Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial
- 18 March 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 377 (9769), 924-931
- https://doi.org/10.1016/s0140-6736(10)62305-7
Abstract
No abstract availableFunding Information
- Novo Nordisk
This publication has 14 references indexed in Scilit:
- Full Accounting of Diabetes and Pre-Diabetes in the U.S. Population in 1988–1994 and 2005–2006Diabetes Care, 2009
- Good glycaemic control: an international perspective on bridging the gap between theory and practice in type 2 diabetesCurrent Medical Research and Opinion, 2008
- Is Glycemic Control Improving in U.S. Adults?Diabetes Care, 2008
- Refining basal insulin therapy: what have we learned in the age of analogues?Diabetes/Metabolism Research and Reviews, 2007
- Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studiesDiabetes, Obesity and Metabolism, 2007
- Evaluating risk factors associated with severe hypoglycaemia in epidemiology studies—what method should we use?Diabetic Medicine, 2004
- Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsJournal of Immunological Methods, 2004
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2003
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- The Physiologic Replacement of InsulinThe New England Journal of Medicine, 1989